Report of Foreign Issuer (6-k)
September 11 2017 - 4:42PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
September 11, 2017
001-36686
(Commission file number)
Forward Pharma A/S
(Translation of registrant’s name into English)
Østergade 24A, 1st Floor
1100 Copenhagen K, Denmark
(Address of principal executive office)
________________________________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): Yes [ ] No [ X ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): Yes [ ] No [ X ]
Indicate by check mark whether by furnishing the information contained in this Form,
the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934. Yes [ ] No [ X ]
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): N/A
Item 1. Company Presentation
On September 11, 2017, Forward Pharma A/S (the “Company”)
made available an updated investor presentation on its website. A copy of the investor presentation is attached hereto as Exhibit
99.1.
The fact that this presentation is being made available and filed herewith
should not be deemed an admission as to the materiality of any information contained in the materials. The information contained
in the presentation is being provided as of September 11, 2017 and the Company does not undertake any obligation to update the
presentation in the future or to update forward-looking statements to reflect subsequent actual results.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: September 11, 2017
|
Forward Pharma A/S
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Claus Bo Svendsen
|
|
|
|
Name: Claus Bo Svendsen
|
|
|
Title: Chief Executive Officer
|
EXHIBIT INDEX
99.1
Investor Presentation dated September 11, 2017
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Forward Pharma AS (NASDAQ:FWP)
Historical Stock Chart
From Apr 2023 to Apr 2024